Проблема полиморбидности – вызов современной медицине


Е.И. Тарловская

ФГБОУ ВО «Нижегородская государственная медицинская академия», кафедра внутренних болезней, г. Нижний Новгород
В статье представлен обзор данных, касающихся полиморбидности. Показано, что старение является основным фактором риска для полиморбидности и что полиморбидность связана с более высокими показателями смертности, инвалидности, с побочными эффектами лечения, с повышенным использованием ресурсов системы здравоохранения, а также с более низким качеством жизни. Обсуждаются вопросы эффективного лечения людей с множественными хроническими заболеваниями. Обоснована необходимость клинических испытаний, включающих больных с множественными хроническими заболеваниями, и разработка новых клинических рекомендаций, на которые могли бы опираться практические врачи при лечении полиморбидных пациентов.
Ключевые слова: принцип Ариадны, де-предписание, терапевтическая конкуренция, полиморбидность, полипрагмазия, лекарственное взаимодействие, коморбидность
Полный текст статьи доступен
в "Библиотеке Врача"

Литература

  1. Fabbri E., Zoli M., Gonzalez-Freire M., Salive M.E., Studenski S.A., Ferrucci L. Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. J. Am. Med. Dir. Assoc. 2015;16(8):640–7.
  2. Smith S.M., Wallace E., O’Dowd T., Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev. 2016;3:CD006560.
  3. Boyd C.M., Ritchie C.S., Tipton E.F. From bedside to bench: summary from the Аmerican geriatrics society/National institute on aging research conference on comorbidity and multiple morbidity in older adults. Aging Clin. Exp. Res. 2008;20:181–8.
  4. McPhail S.M. Multimorbidity in chronic disease: impact on health care resources and costs. Risk Manag. Healthc. Policy. 2016;9:143–56.
  5. Le Reste J.Y., Nabbe P., Manceau B. The European General Practice Research Network presents a comprehensive definition of multimorbidity in family medicine and long term care, following a systematic review of relevant literature. J. Am. Med. Dir. Assoc. 2013;14:319–25.
  6. Barnett K., Mercer S.W., Norbury M. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43.
  7. Buffel du Vaure C., Ravaud P., Baron G., Barnes C., Gilberg S., Boutron I. Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis. BMJ Open. 2016;6(3):e010119
  8. Anderson G. Chronic care: making the case for ongoing care. Princeton, NJ: Robert Wood Johnson Foundation; 2010. p. 43.
  9. Van Oostrom S.H., Picavet H.S., van Gelder B.M., Lemmens L.C., Hoeymans N., van Dijk C.E., Verheij R.A., Schellevis F.G., Baan C.A. Multimorbidity and comorbidity in the Dutch population – data from general practices. BMC Public Health. 2012;12:715.
  10. London: National Institute for Health and Care Excellence (UK); 2016 Sep. Clinical guidelines. Multimorbidity: assessment, prioritisation and management of care for people with commonly occurring multimorbidity. https://www.ncbi.nlm.nih.gov/pubmed/27683922
  11. Booth H.P., Prevost A.T., Gulliford M.C. Impact of body mass index on prevalence of multimorbidity in primary care: Cohort study. Fam. Pract. 2014;31:38–43.
  12. Cimarras-Otal C., Calderón-Larrañaga A., Poblador-Plou B., González-Rubio F., Gimeno-Feliu L.A., Arjol-Serrano J.L., Prados-Torres A. Association between physical activity, multimorbidity, self-rated health and functional limitation in the Spanish population. BMC Public Health. 2014;14:1170.
  13. Prados-Torres A., Calderón-Larrañaga A., Hancco-Saavedra J. Multimorbidity patterns: A systematic review. J. Clin. Epidemiol. 2014;67:254–66.
  14. Van den Akker M., Buntinx F., Metsemakers J.F., Roos S., Knottnerus J.A .Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J. Clin. Epidemiol. 1998;51:367–75.
  15. Vogeli C.l., Shields A.E., Lee T.A., Gibson T.B., Marder W.D., Weiss K.B., Blumenthal D. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J. Gen. Intern. Med. 2007;3:391–5.
  16. Barnes P.J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med. 2014;35(1):71–86.
  17. Houghton A.M. Mechanistic links between COPD and lung cancer. Nat. Rev. Cancer. 2013;13(4):233–45.
  18. Inoue D., Watanabe R., Okazaki R. COPD and osteoporosis: links, risks, and treatment challenges. Int. J. Chron. Obstruct. Pulmon. Dis. 2016;11:637–4.
  19. Savransky V., Nanayakkara A., Li J., Bevans S., Smith P.L., Rodriguez A., Polotsky V.Y. Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care. Med. 2007;175:1290–7.
  20. Gaddam S., Gunukula S.K., Lohr J.W., Arora P., Gaddam S., Gunukula S.K., Lohr J.W., Arora P. Prevalence of chronic kidney disease in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm. Med. 2016;16(1):158.
  21. Miller J., Edwards L.D., Agustí A., Bakke P., Calverley P.M., Celli B., Coxson H.O., Crim C., Lomas D.A., Miller B.E., Rennard S., Silverman E.K., Tal-Singer R., Vestbo J., Wouters E., Yates J.C., Macnee W. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013;107(9):1376–84.
  22. Guettier J.M., Georgopoulos Ben-Noun L. Characteristics of comorbidity in adult asthma. Public Health Rev. 2001;29(1):49–61.
  23. Partnership for solutions. Chronic conditions: making the case for ongoing care: Robert Wood Johnson Foundation. 2002.
  24. Sokal J., Messias E., Dickerson F.B., Kreyenbuhl J., Brown C.H., Goldberg R.W. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J. Nerv. Ment. Dis. 2004;192(6):421–7.
  25. Tellez-Zenteno J.F., Matijevic S., Wiebe S. Somatic comorbidity of epilepsy in the general population in Canada. Epilepsia. 2005;46(12):1955–62.
  26. Nunes B.P., Flores T.R., Mielke G.I. Thumé E., Facchini L.A. Multimorbidity and mortality in older adults: A systematic review and meta-analysis. Arch. Gerontol. Geriatr. 2016;67:130–8.
  27. Арутюнов А.Г., Драгунов Д.О., Арутюнов Г.П., Рылова А.К., Пашкевич Д.Д., Витер К.В., Деревянченко М.В., Инина Л.И., Соловьева О.Е., Стаценко М.Е. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015;22(5):12–21.
  28. Чесникова А.И., Батюшин М.М., Терентьев В.П. Артериальная гипертензия и коморбидность: современное состояние проблемы. Артериальная гипертензия. 2016;22(5):432–40.
  29. Симонова Ж.Г., Мартусевич А.К., Тарловская Е.И. Клинико-патогенетические аспекты течения ишемической болезни сердца у больных в сочетании с язвенной болезнью. Терапевтический архив. 2014;1:33–6.
  30. Saseen J.J., Agashivala N., Allen R.R., Ghushchyan V., Yadao A.M., Nair K.V. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012;51(11):2004–12.
  31. Тарловская Е.И., Одегова А.А. Особенности ремоделирования сердца у больных бронхиальной астмой средней степени тяжести в сочетании с артериальной гипертензией. Сердечная недостаточность. 2016;17(1):10–4.
  32. Тарловская Е.И., Сапожникова И.Е., Тарловский А.К. Варианты ремоделирования миокарда левого желудочка у пациентов с артериальной гипертензией и нарушениями углеводного обмена. Кардиология. 2013;53(8):44–8.
  33. Benfante A., Basile M., Battaglia S., Spatafora M., Scichilone N. Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics. Ther. Clin. Risk Manag. 2016;12:1553–62.
  34. Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American geriatrics society: American geriatrics society expert panel on the care of older adults with multimorbidity. J. Am. Geriatr. Soc. 2012;60(10):1957–68.
  35. Greenfield S., Billimek J., Pellegrini F., Franciosi M., De Berardis G., Nicolucci A., Kaplan S.H. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann. Intern. Med. 2009;151(12):854–60.
  36. Andrews J.C., Schünemann H.J., Oxman A.D., Pottie K., Meerpohl J.J., Coello P.A., Rind D., Montori V.M., Brito J.P., Norris S., Elbarbary M., Post P., Nasser M., Shukla V., Jaeschke R., Brozek J., Djulbegovic B., Guyatt G. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J. Clin. Epidemiol. 2013;66:726–35.
  37. Симонова Ж.Г., Мартусевич А.К., Тарловская Е.И Сочетанная кардиоваскулярная и гастродуоденальная патология. Киров, 2013. 132 с.
  38. Dumbreck S., Flynn A., Nairn M., Wilson M., Treweek S., Mercer S.W., Alderson P., Thompson A., Payne K., Guthrie B. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350:h949.
  39. Russell L.B., Suh D.C., Safford M.A. Time requirements for diabetes self-management: too much for many? J. Fam. Pract. 2005;54:52–6.
  40. Boyd C.M., Darer J., Boult C. Clinical practice guidelines and quality of care for older patients . JAMA. 2005;294:716–24.
  41. American geriatrics society expert panel on the care of older adults with multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. J. Am. Geriatr. Soc. 2012;60:e1–25.
  42. Fitzgerald S.P., Bean N.G. An analysis of the interactions between individual comorbidities and their treatments-implications for guidelines and polypharmacy. J. Am. Med. Dir. Assoc. 2010;11:475–84.
  43. Rochon P.A., Gurwitz J.H. Optimising drug treatment for elderly people: The prescribing cascade. BMJ. 1997;315:1096–9.
  44. Lorgunpai S.J., Grammas M., Lee D.S. Potential therapeutic competition in community-living older adults in the US: Use of medications that may adversely affect a coexisting condition. PLoS One.2014;9:e89447.
  45. Winklmayer W.C., Setoguchi S., Levin R., Solomon D.H. Comparisons of cardiovascular outcomes in elderly patients with diabetes who initiated Rosiglitazone vs Pioglitazone therapy. Arch. Intern. Med. 2008;168:2368–75.
  46. Gurwitz J.H., Field T.S., Harrold L.R., Rothschild J., Debellis K. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107–16.
  47. McPhail S.M., Schippers M., Marshall A.L. Age, physical inactivity, obesity, health conditions, and health-related quality of life among patients receiving conservative management for musculoskeletal disorders. Clin. Interv. Aging. 2014;9:1069–80.
  48. Holmes H.M., Min L.C., Yee M., Varadhan R., Basran J., Dale W., Boyd C.M. Rationalizing prescribing for older patients with multimorbidity: Considering time to benefit. Drugs Aging. 2013;30:655–66.
  49. Schuling J., Gebben H., Veehof L.J., Haaijer-Ruskamp F.M. Deprescribing medication in very elderly patients with multimorbidity: The view of Dutch GPs. A qualitative study. BMC Fam. Pract. 2012;13:56.
  50. Reeve E., Wiese M.D. Benefits of deprescribing on patients’ adherence to medications. Int. J. Clin. Pharm. 2014;36:26–9.
  51. Graves T., Hanlon J.T., Schmader K.E. Adverse events after discontinuing medications in elderly outpatients. Arch. Intern. Med. 1997;157:2205–10.
  52. Bain K.T., Holmes H.M., Beers M.H., Maio V., Handler S.M., Pauker S.G. Discontinuing medications: A novel approach for revising the prescribing stage of the medication-use process. J. Am. Geriatr. Soc. 2008;56:1946–52.
  53. Muth C., van den Akker M., Blom J.W., Mallen C.D., Rochon J., Schellevis F.G., Becker A., Beyer M., Gensichen J., Kirchner H., Perera R., Prados-Torres A., Scherer M., Thiem U., van den Bussche H., Glasziou P.P. The Ariadne principles: how to handle multimorbidity in primary care consultations. BMC Med. 2014;12:223
  54. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K., Falk V., Filippatos G., Fonseca C. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012;33:1787–847.
  55. Horne R., Weinman J., Barber N., Elliott R., Morgan M., Cribb A., Kellar I.: Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS service delivery and organisation R & D (NCCSDO). 2005.
  56. Boyd C.M., McNabney M.K., Brandt N., Correa-de-Araujuo R., Daniel M., Epplin J., Fried T.R., Goldstein M.K., Holmes H.M., Ritchie C.S., Shega J.W. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American geriatrics society expert panel on the care of older adults with multimorbidity. J. Am. Geriatr. Soc. 2012;60:1–25.
  57. National Heart Foundation of Australia (2010). Multidisciplinary care for people with chronic heart failure. Principles and recommendations for best practice. http://www.heartfoundation.org.au/SiteCollectionDocuments/Multidisciplinary-care-for-people-with-CHF.pdf accessed 2012 November 16.
  58. Wittenberg R. The challenge of measuring multi-morbidity and its costs. Isr. J. Health Policy Res. 2015;4:1.
  59. Sloane P.D., Oudenhoven M.D., Broyles I., McNabney M. Challenges to cost-effective care of older adults with multiple chronic conditions: perspectives of Program of All-Inclusive Care for the Elderly medical directors. J. Am. Geriatr. Soc. 2014;62(3):564–5.
  60. Huntley A.L., Johnson R., Purdy S., Valderas J.M., Salisbury C. Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. Ann. Fam. Med. 2012;10(2):134–41.
  61. Chan D.K., Chong R., Basilikas J., Mathie M., Hung W.T. Survey of major chronic illnesses and hospital admissions via the emergency department in a randomized older population in Randwick, Australia. Emerg. Med. 2002;14(4):387–92.
  62. Rapoport J., Jacobs P., Bell N.R., Klarenbach S. Refining the measurement of the economic burden of chronic diseases in Canada. Chronic. Dis. Can. 2004;25(1):13–21.
  63. Schneider K.M., O’Donnell B.E., Dean D. Prevalence of multiple chronic conditions in the United States’ medicare population. Health Qual. Life Outcomes. 2009;7(82):82.
  64. Schoen C., Osborn R., Squires D., Doty M.M., Pierson R, Applebaum S. How health insurance design affects access to care and costs, by income, in eleven countries. Health Aff. 2010;29(12):2323–34.
  65. Rogowski J., Lillard L.A., Kington R. The financial burden of prescription drug use among elderly persons. Gerontologist. 1997;37(4):475–82.
  66. O’Toole J., Hambly R., Cox A.M., O’Shea B., Darker C. Methadone-maintained patients in primary care have higher rates of chronic disease and multimorbidity, and use health services more intensively than matched controls. Eur. J. Gen. Pract. 2014;20(4):275–80.
  67. Smith S.M., Soubhi H., Fortin M., Hudon C., O’Dowd T. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. BMJ. 2012;345:e5205.
  68. Panagioti M., Richardson G., Murray E., Rogers A., Kennedy A., Newman S., Small N., Bower P. Reducing Care Utilisation through Self-management Interventions (RECURSIVE): a systematic review and meta-analysis. Southampton, UK: Queen’s Printer and Controller of HMSO, 2014.
  69. Raftery J.P., Yao G.L., Murchie P., Campbell N.C., Ritchie L.D. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial. BMJ. 2005;330(7493):707.
  70. Fagan K., Zhao E.Y., Horsfall L., Ruffin B.J., Kruger M.S., McPhail S.M., O’Rourke P., Ballard E., Irvine K.M., Powell E.E. Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change? Intern. Med. J. 2014;44(9):865–72.
  71. Price E., Baker R., Krause J., Keen C. Organisation of services for people with cardiovascular disorders in primary care: transfer to primary care or to specialist-generalist multidisciplinary teams? BMC Fam. Pract. 2014;15:158.
  72. May C.R., Eton D.T., Boehmer K. Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness. BMC Health Serv. Res. 2014;14(1):1–11.
  73. Duerden M., Avery T., Payne R. Polypharmacy and Medicines Optimisation. Making it Safe and Sound. The King’s Fund; 2013. http://www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf. Accessed September 5th 2014.


Об авторах / Для корреспонденции

Екатерина Иосифовна Тарловская, д.м.н., профессор, и.о. зав. кафедрой внутренних болезней ФГБОУ ВО «Нижегородская государственная медицинская академия». Адрес: 603005, г. Нижний Новгород, пл. Минина и Пожарского, д. 10/1. Тел.: (831) 437-08-86. E-mail: etarlovskaya@mail.ru


Похожие статьи

К содержанию номера

Бионика Медиа